Hofseth BioCare ASA (OSL:HBC)
Norway · Delayed Price · Currency is NOK 1.300
-0.045 (-3.35%)
Sep 14, 2026, 4:17 PM CET
Hofseth BioCare ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 237.81 | 254.43 | 256.83 | 190.82 | 119.13 | 76.88 |
Other Revenue | 4.39 | 1.91 | 8.71 | 27.7 | 1.32 | 10.74 |
| 242.2 | 256.34 | 265.54 | 218.51 | 120.45 | 87.62 | |
Revenue Growth | -7.58% | -3.46% | 21.52% | 81.42% | 37.47% | 26.52% |
Cost of Revenue | 168.37 | 177.65 | 189.81 | 165 | 102.49 | 77.05 |
Gross Profit | 73.83 | 78.69 | 75.73 | 53.51 | 17.96 | 10.57 |
Selling, General & Admin | 107.18 | 102.29 | 91.37 | 76.25 | 76.03 | 60.35 |
Other Operating Expenses | 40.1 | 49.34 | 49.66 | 43.38 | 40.13 | 39.43 |
Operating Expenses | 188.22 | 190.95 | 180.81 | 156.04 | 146.39 | 129.13 |
Operating Income | -114.39 | -112.25 | -105.08 | -102.53 | -128.43 | -118.56 |
Interest Expense | -27.65 | -22.83 | -15.69 | -7.54 | -9.95 | -9.39 |
Interest & Investment Income | 1.77 | 2 | 0.79 | 0.55 | 0.65 | 0.61 |
Earnings From Equity Investments | 0.33 | 2.15 | -7.48 | 2.54 | -0.2 | 0.03 |
Currency Exchange Gain (Loss) | 3.67 | -3.68 | 2.16 | 0.3 | 0.74 | 0.91 |
Other Non Operating Income (Expenses) | -0 | -0 | - | -0 | - | -0.06 |
EBT Excluding Unusual Items | -136.27 | -134.61 | -125.3 | -106.69 | -137.2 | -126.46 |
Asset Writedown | -0.09 | -0.09 | - | - | -0.19 | - |
Pretax Income | -136.37 | -134.71 | -125.3 | -106.69 | -137.39 | -126.46 |
Income Tax Expense | 0.18 | 0.18 | - | - | - | - |
Earnings From Continuing Operations | -136.55 | -134.88 | -125.3 | -106.69 | -137.39 | -126.46 |
Minority Interest in Earnings | 0 | 0 | 0 | 0 | 0 | 0 |
Net Income | -136.55 | -134.88 | -125.3 | -106.68 | -137.39 | -126.46 |
Net Income to Common | -136.55 | -134.88 | -125.3 | -106.68 | -137.39 | -126.46 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 411 | 411 | 411 | 395 | 375 | 358 |
Shares Outstanding (Diluted) | 411 | 411 | 412 | 395 | 375 | 358 |
Shares Change | - | -0.20% | 4.26% | 5.43% | 4.72% | 7.25% |
EPS (Basic) | -0.33 | -0.33 | -0.30 | -0.27 | -0.37 | -0.35 |
EPS (Diluted) | -0.35 | -0.33 | -0.30 | -0.27 | -0.37 | -0.35 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -26.86 | -47.54 | -13.84 | -5.43 | -49.19 | -84.7 |
Free Cash Flow Per Share | -0.07 | -0.12 | -0.03 | -0.01 | -0.13 | -0.24 |
Gross Margin | 30.48% | 30.70% | 28.52% | 24.49% | 14.91% | 12.06% |
Operating Margin | -47.23% | -43.79% | -39.57% | -46.92% | -106.63% | -135.32% |
Profit Margin | -56.38% | -52.62% | -47.19% | -48.82% | -114.06% | -144.34% |
Free Cash Flow Margin | -11.09% | -18.55% | -5.21% | -2.49% | -40.84% | -96.67% |
EBITDA | -98.63 | -98.11 | -90.71 | -89.83 | -118.46 | -104.57 |
EBITDA Margin | -40.72% | -38.27% | -34.16% | -41.11% | -98.35% | -119.35% |
D&A For EBITDA | 15.76 | 14.14 | 14.37 | 12.7 | 9.97 | 14 |
EBIT | -114.39 | -112.25 | -105.08 | -102.53 | -128.43 | -118.56 |
EBIT Margin | -47.23% | -43.79% | -39.57% | -46.92% | -106.63% | -135.32% |
Revenue as Reported | 242.2 | 256.34 | 265.54 | 218.51 | 120.45 | 87.62 |
Advertising Expenses | - | 13.88 | 15.33 | 13.49 | 15.04 | 13.03 |